IGF2R overexpression
|
Gastric Cancer
|
IGF2R overexpression
|
Gastric Cancer
|
ECF Resistant: C3 – Early Trials
|
ECF Resistant: C3 – Early Trials
|
IGF2R overexpression
|
AML
|
IGF2R overexpression
|
AML
|
etoposide IV Sensitive: D – Preclinical
|
etoposide IV Sensitive: D – Preclinical
|
IGF2R overexpression
|
AML
|
IGF2R overexpression
|
AML
|
SA033 Sensitive: D – Preclinical
|
SA033 Sensitive: D – Preclinical
|